Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This clinical trial evaluates a high intensity electronic health (eHealth) intervention program for reducing learning disparities in children with cancer. Most children with leukemia and lymphoblastic lymphoma can be cured due to advancements in diagnosis and treatment. However, because treatments for these conditions target the central nervous system, these children are at increased risk for developing neurocognitive late effects (problems with attention, thinking, learning, and remembering). Fortunately, many survivors do well, but some children continue to struggle with learning and have academic difficulties after their cancer treatments. The purpose of this research study is to see whether providing parents with educational knowledge and parenting tips using videoconferencing and a special website better helps their cancer survivor child in learning and school achievement compared to typical services.
Full description
PRIMARY OBJECTIVE:
I. Determine the effectiveness of high intensity program (HIP)-eHealth on pediatric cancer survivors' learning and school-related outcomes up to 12 months post-enrollment.
SECONDARY OBJECTIVES:
I. Determine the effectiveness of HIP-eHealth on parental efficacy up to 12 months post-enrollment.
II. Examine the extent to which parents' self-reported efficacy and/or children's use of online learning activities correlates with the children's school functioning.
III. Examine differences in HIP-eHealth uptake and effects across socio-demographic groups.
OUTLINE:
PRE-STUDY: Parent-child dyads attend 4 intervention sessions over 10 weeks and provide feedback in support of intervention refinement.
Parent-child dyads are randomized to 1 of 2 arms.
ARM I: Patients and parents undergo high intensity eHealth intervention through the interactive website and via videoconferencing for 30-50 minutes once every 3 to 4 weeks for up to 5 sessions over 6 months. Patients and parents also receive usual care. After 6 months, parents attend booster sessions at months 7, 9, and 11.
ARM II: Patients and parents receive usual care.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Documented informed consent of the participant and/or legally authorized representative
Primary participating parent/caregiver is English- or Spanish-speaking (any race/ethnicity)
Child is aged 6-12 years (yr.) (for the website usability pre-study, child is age 8 - 12 yrs.)
Child understands English (but can be bilingual)
Child treated for acute leukemia (e.g., acute lymphoblastic leukemia, acute myelogenous leukemia) or lymphoblastic lymphoma
Child is in cancer remission and has completed cancer therapies, including maintenance treatment
Primary participating parent/caregiver has daily contact with the child
Child is enrolled in school
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
342 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal